1 / 17

HPTN Future Directions

HPTN Future Directions. January 22, 2003 Bethesda, MD. What’s Next. Building on accomplishments Short term goals Science completion/implementation Long term goals Science generation. What Has Worked. Science generation

cathy
Télécharger la présentation

HPTN Future Directions

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. HPTN Future Directions January 22, 2003 Bethesda, MD

  2. What’s Next • Building on accomplishments • Short term goals • Science completion/implementation • Long term goals • Science generation

  3. What Has Worked • Science generation • Including input from a variety of sources, concepts, review, quality of protocols, multidisciplinary inputs • Focus on international infrastructure • Cooperative agreements as a funding mechanism • Multisdisciplinary integration • Governance

  4. Short Term Goals • Goal 1: Complete Science in Progress • Goal 2: Capacity Building • Goal 3: Science Generation • Goal 4: Science Implementation

  5. Goal 1: Completing Science in Progress • 012: Perinatal: Nevirapine • 015: Behavioral: EXPLORE • 016A: Microbicides/Behavioral: Couples Counseling • 024: Perinatal: Chorioamnionitis • 037: Substance use: Peer networks • 032/049/050: Microbicides Phase I

  6. Goal 2: Capacity Building • Working in places where incidence is high • We need to stay there and ensure that we can do the important trials • Laboratory • GCP • GLP • Ethics • Community  • continuous improvement process • network is ready for prevention clinical trials

  7. Goal 2: Capacity Building • Preparedness studies • Cohort identification and follow-up • 033: China, India, Russia • 034: India • 036: Peru • 055: South Africa, Tanzania, Zambia • 016a: Zimbabwe, Malawi (Lilongwe and Blantyre)

  8. Goal 3: Science Generation • Working Groups • Met • Assessed • Identified gaps • Matched gaps to HPTN strengths and mission • Stimulated and competed concepts • Brought concepts to protocol stage • Spun off others into the R01 pool

  9. Goal 4: Science Implementation • 035: Microbicides: BufferGel and Pro2000 • 039: STDs (R01): Herpes • 040: Perinatal: Postnatal ART • 043: Behavioral (R01): Community VCT • 046: Perinatal: Nevirapine during Breastfeeding • 052: Antiretrovirals: Reducing Transmission • 054: Perinatal: Access to NVP with and without HIV VCT • 056: Rectal Microbicides

  10. Long-Term: Science Generation • Unmet needs • Multidisciplinary • Array of epidemiological environments • Implemented and completed with quality • Landmark trials: Phase III HIV incidence endpoint

  11. If Not in This Network, Then Where Will Phase III Prevention Trials Occur? • The field needs Phase III prevention trials • Industry not interested • Need to be multidisciplinary • Beyond any one academic institution • Beyond any one NIH institute • Beyond any one network

  12. What Would We Change? • New ‘rapid discovery’ regulatory model to facilitate protocols with FDA • Resources commensurate with the scope of responsibilities as Phase III non-vaccine network • Product procurement contract to obtain study products more quickly

  13. In Conclusion • This is an excellent use of funds • Important to preserve the triple track • Treatment/ Vaccines/ Prevention • Focus on prevention is of vital significance • The network is the right approach • This network represents the best in the field • HPTN has been productive, despite significant barriers and challenges

  14. Are we in the ballpark? • High quality trials • Definitive • Meeting FDA standards • With HIV seroincidence endpoints • Resources need to match expectations and breadth of the agenda

  15. Comparable Efforts? • HSV Vaccine (GSK) : $200m • HIV Vaccines (VaxGen): $200m • ID Prevention Trial: $45m • HIV Interleukin-2 (Chiron): $160m • 035: $60-100m (est) • 052: $100m (est)

More Related